14 studies found for:    16014882 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
Condition: Non-Small-Cell Lung Carcinoma
Intervention: Drug: OSI-774 (Tarceva)
2 Active, not recruiting Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Conditions: Adenocarcinoma;   Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
3 Recruiting Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
Condition: Lung Cancer
Intervention: Other: Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes
4 Completed Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Erlotinib;   Drug: Bevacizumab
5 Completed OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
6 Completed A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: sunitinib and rapamycin (Drug will be held)
7 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
8 Unknown  Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Procedure: FDG-/FLT-PET
9 Terminated Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
Conditions: Esophageal Neoplasms;   Esophageal Diseases
Interventions: Drug: Erlotinib;   Drug: Avastin
10 Active, not recruiting Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Drug: Docetaxel
11 Unknown  Tarceva Italian Lung Optimization tRial
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Erlotinib;   Drug: Docetaxel
12 Withdrawn Erlotinib for Treatment of Psoriasis
Condition: Psoriasis
Interventions: Drug: erlotinib;   Other: placebo tablet
13 Active, not recruiting Erlotinib and Temsirolimus for Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Temsirolimus
14 Recruiting Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Docetaxel

Indicates status has not been verified in more than two years